Tobacco industry efforts undermining evidence linking secondhand smoke with cardiovascular disease

Circulation

Volumn 116, Issue 16, 2007, Pages 1845-1854

  Tong, Elisa K ^a   Glantz, Stanton A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epidemiology; Lipids; Platelets; Public policy; Tobacco smoke pollution

Indexed keywords

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FUNDING; HUMAN; INFLAMMATION; LUNG FUNCTION; MUTAGENICITY; OXIDATIVE STRESS; PASSIVE SMOKING; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; THROMBOCYTE AGGREGATION; TOBACCO INDUSTRY;

BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; CONFLICT OF INTEREST; HUMANS; PUBLIC OPINION; RISK FACTORS; TOBACCO INDUSTRY; TOBACCO SMOKE POLLUTION;

EID: 37349012185     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.715888     Document Type: Article

References (151)

1. Gillis CR, Hole DJ, Hawthorne VM, Boyle P. The effect of environmental tobacco smoke in two urban communities in the west of Scotland. Eur J Respir Dis Suppl. 1984;133:121-126.
2. Garland C, Barrett-Connor E, Suarez L, Criqui MH, Wingard DL. Effects of passive smoking on ischemic heart disease mortality of nonsmokers: a prospective study. Am J Epidemiol. 1985;121:645-650.
3. Wells AJ. An estimate of adult mortality from passive smoking. Environ Int. 1988;14:249-265.
4. Glantz SA, Parmley WW. Passive smoking and heart disease. Circulation. 1991;83:1-12.
5. Taylor AE, Johnson CE, Kazemi H. Environmental tobacco smoke and cardiovascular disease: a position paper from the Council on Cardiopulmonary and Critical Care, American Heart Association. Circulation. 1992;86:699-702.
6. California Environmental Protection Agency. Health Effects of Exposure to Environmental Tobacco Smoke: Final Report. San Francisco, Calif: Office of Environmental Health Hazard Assessment; 1997.
7. California Environmental Protection Agency. Proposed Identification of Environmental Tobacco Smoke as a Toxic Air Contaminant. San Francisco, Calif: Office of Environmental Health Hazard Assessment; 2005. Available at: www.arb.ca.gov/regact/ets2006/ets2006.htm. Accessed May 15, 2007.
8. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Washington, DC: US Department of Health and Human Services; 2006.
9. Whincup PH, Gilg JA, Emberson JR, Jarvis MJ, Feyerabend C, Bryant A, Walker M, Cook DG. Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement. BMJ. 2004;329:200-205.
10. Glantz SA, Parmley WW. Passive smoking and heart disease: mechanisms and risk. JAMA. 1995;273:1047-1053.
11. Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ. 1997;315:973-980.
12. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation. 2005;111:2684-2698.
13. Pechacek TF, Babb S. How acute and reversible are the cardiovascular risks of secondhand smoke? BMJ. 2004;328:980-983.
14. Raupach T, Schafer K, Konstantinides S, Andreas S. Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm. Eur Heart J. 2006;27:386-392.
15. Ong EK, Glantz SA. Tobacco industry efforts subverting International Agency for Research on Cancer's second-hand smoke study. Lancet. 2000;355:1253-1259.
16. Muggli ME, Hurt RD, Blanke DD. Science for hire: a tobacco industry strategy to influence public opinion on secondhand smoke. Nicotine Tob Res. 2003;5:303-314.
17. Fichtenberg CM, Glantz SA. Effect of smoke-free workplaces on smoking behaviour: systematic review. BMJ. 2002;325:188.
18. Barnoya J, Glantz S. Tobacco industry success in preventing regulation of secondhand smoke in Latin America: the "Latin Project." Tob Control. 2002;11:305-314.
19. Barnes DE, Bero LA. Industry-funded research and conflict of interest: an analysis of research sponsored by the tobacco industry through the Center for Indoor Air Research. J Health Polit Policy Law. 1996;21:515-542.
20. Hirschhorn N, Bialous SA, Shatenstein S. Philip Morris' new scientific initiative: an analysis. Tob Control. 2001;10:247-252.
21. Hirschhorn N, Bialous SA, Shatenstein S. The Philip Morris External Research Program: results from the first round of projects. Tob Control. 2006;15:267-269.
22. Muggli ME, Hurt RD, Repace J. The tobacco industry's political efforts to derail the EPA report on ETS. Am J Prev Med. 2004;26:167-177.
23. Hong MK, Bero LA. How the tobacco industry responded to an influential study of the health effects of secondhand smoke. BMJ. 2002;325:1413-1416.
24. Bero LA, Glantz S, Hong MK. The limits of competing interest disclosures. Tob Control. 2005;14:118-126.
25. Tong EK, England L, Glantz SA. Changing conclusions on secondhand smoke in a sudden infant death syndrome review funded by the tobacco industry. Pediatrics. 2005;115:e356-e366.
26. Malone RE, Balbach ED. Tobacco industry documents: treasure trove or quagmire? Tob Control. 2000;9:334-338.
27. Occupational Safety and Health Administration. Indoor air quality. Available at: http://www.osha.gov/pls/oshaweb/owadisp.show_document? p_table=FEDERAL_REGISTER&p_id=13369. Accessed December 15, 2006.
28. Tobacco Institute. OSHA projects. August 1991. Lorillard. Available at: http://legacy.library.ucsf.edu/tid/ews21e00. Accessed December 15, 2006.
29. Rowland D, for Rothmans International. IEMC: Brief-ETS and CHD. May 30, 1991. Brown and Williamson. Available at: http://legacy.library.ucsf.edu/tid/ ekj33f00. Accessed December 15, 2006.
30. Echobichon D, Wu J. Environmental tobacco smoke. In: Proceedings of the International Symposium at McGill University; November 3-4, 1989; Lexington, Mass: Lanham, Md: Lexington Books; 1990.
31. Philip Morris. Discussion topics working outline 920224 meeting: February 24, 1992. Available at: http://legacy.library.ucsf.edu/tid/pei72a00. Accessed December 15, 2006.
32. Mantel N. Dubious evidence of heart and cancer deaths due to passive smoking. J Clin Epidemiol. 1992;45:809-813.
33. Glantz SA, Parmley WW. Passive smoking causes heart disease and lung cancer. J Clin Epidemiol. 1992;45:815-819.
34. Glantz SA, Slade J, Bero LA, Hanauer P, Barnes DE, eds. The Cigarette Papers. Berkeley, Calif: University of California Press; 1996. 35. Gori GB. Environmental tobacco smoke and coronary heart syndromes: absence of an association. Regul Toxicol Pharmacol. 1995;21:281-295.
35. Tobacco Institute. Gori GB. [Gio Gori curriculum vitae]. August 18, 1993. Available at: http://legacy.library.ucsf.edu/tid/exy52f00. Accessed December 15, 2006.
36. Penn A. Center for Indoor Air Research, NY University Medical Center. Does ETS promote arteriosclerosis or act as a co-atherogen? February 1989. Lorillard. Available at: http://legacy.library.ucsf.edu/tid/tvq99d00. Accessed December 15, 2006.
37. Penn A, NYU. Does ETS promote arteriosclerosis or act as a co-atherogen? March 1995. Lorillard. Available at: http://legacy.library.ucsf.edu/tid/ zqg64a00. Accessed December 15, 2006.
38. Penn A, Snyder CA. Inhalation of sidestream cigarette smoke accelerates development of arteriosclerotic plaques. Circulation. 1993;88:1820-1825.
39. Coggins CR. Sidestream cigarette smoke. Circulation. 1994;89:2943. Letter.
40. Bialous SA, Glantz S. ASHRAE standard 62: tobacco industry's influence over national ventilation standards. Tob Control. 2002;11:315-328.
41. Holcomb LC. Indoor air quality and environmental tobacco smoke: concentration and exposure. Environ Int. 1993;19:9-40.
42. Penn A, Snyder CA. Reply to sidestream cigarette smoke. Circulation. 1994;89:2943-2944.
43. Stolberg S. Researchers try to separate smoking fact from fiction. Los Angeles Times. May 28, 1994.
44. Penn A, Chen LC, Snyder CA. Inhalation of steady-state sidestream smoke from one cigarette promotes arteriosclerotic plaque development. Circulation. 1994;90:1363-1367.
45. Penn A, Snyder CA. 1,3 Butadiene, a vapor phase component of environmental tobacco smoke, accelerates arteriosclerotic plaque development. Circulation. 1996;93:552-557.
46. Coggins CR. 1,3 Butadiene and environmental tobacco smoke. Circulation. 1997;95:275. Letter.
47. Penn A, Snyder CA. Response to 1,3 butadiene and environmental tobacco smoke. Circulation. 1997;95:275-276.
48. Stone R. Study implicates second-hand smoke. Science. 1994;264:30.
49. Diethelm PA, Rielle JC, McKee M. The whole truth and nothing but the truth? The research that Philip Morris did not want you to see. Lancet. 2005;366:86-92.
50. Haussmann H. Atherosclerosis research at INBIFO/CRC. June 24, 1994. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/ach79e00. Accessed December 15, 2006.
51. CIAR Board. CIAR board meeting 940426. April 26, 1994. Lorillard. Available at: http://legacy.library.ucsf.edu/tid/mhj01e00. Accessed December 15, 2006.
52. Witorsch P. GUMC Pharmacology Laboratory research proposals for CIAR environmental tobacco smoke (ETS) exposure of nonsmokers and subsequent cardiovascular effects. March 1994. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/yrh35e00. Accessed December 15, 2006.
53. Gori GB. Acute cardiovascular and performance effects in ETS exposed nonsmokers. February 22, 1994. Lorillard. Available at: http://legacy.library. ucsf.edu/tid/can33c00. Accessed December 15, 2006.
54. Center for Indoor Air Research. Center for Indoor Air Research. Center for Indoor Air Research Board of Directors meeting. July 27, 1994. Lorillard. Available at: http://legacy.library.ucsf.edu/tid/yvf30e00. Accessed December 15, 2006.
55. Layard M. Layard Associates. The National Mortality Followback Survey. May 24, 1994. Lorillard. Available at: http://legacy.library.ucsf.edu/tid/ hji01e00. Accessed December 15, 2006.
56. LeVois M, Layard M. Publication bias in the environmental tobacco smoke-coronary heart disease literature. Regul Toxicol Pharmacol. 1995;21:184-191.
57. Layard M. Ischemic heart disease and spousal smoking in the National Mortality Followback Survey. Regul Toxicol Pharmacol. 1995;21:180-183.
58. Glantz SA, Parmley WW. Passive and active smoking: a problem for adults. Circulation. 1996;94:596-598.
59. Steenland K, Thun M, Lally C, Heath CJ. Environmental tobacco smoke and coronary heart disease in the American Cancer Society CPS-II cohort. Circulation. 1996;94:622-628.
60. Thun MJ. Passive smoking: tobacco industry publishes disinformation. BMJ. 2003;327:502-503. Letter.
61. Thun M, Henley J, Apicella L. Epidemiologic studies of fatal and nonfatal cardiovascular disease and ETS exposure from spousal smoking. Environ Health Perspect. 1999;107:841-846.
62. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation. 1997;96:1089-1096.
63. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis. 2003;46:91-111.
64. Tobacco Institute. Tobacco Institute statement in response to "Passive Smoking and Heart Disease" (JAMA. April 5, 1995). RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/wqb13a00. Accessed December 15, 2006.
65. Tobacco Manufacturers' Association. Tobacco Manufacturers' Association. Commentary on the Law, Morris and Wald paper on ETS and ischaemic heart disease summary. November 1997. Philip Morris. Available at: http://legacy.library.ucsf. edu/tid/gpl67e00. Accessed December 15, 2006.
66. Scientific Committee on Tobacco and Health. Report of the Scientific Committee on Tobacco and Health. Washington, DC: Department of Health; 1998.
67. Lee PN, Roe FJ. Environmental tobacco smoke: a critique of Glantz and Parmley. Hum Ecol Risk Assess. 1999;5:171-218.
68. Lee P. Review 1037 subject Ref 8A multiple reviews of the evidence on ETS and heart disease: comments on recent papers by Lee and Roe, Denson, Kawachi, He et al, Bailar, and Mengersen et al. March 25, 1999. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/cff19c00. Accessed December 15, 2006.
69. Dempsey R. LWD. HSC Consultation document: a summary of the key problems and inconsistencies raised by the revised draft of the ACOP. March 1999. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/ojn25c00. Accessed December 15, 2006.
70. Sanders E. New Zealand Document. October 24, 2000. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/pms55c00. Accessed December 15, 2006.
71. Sanders T. WSA Categorization form: ETS heart disease. October 28, 1999. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/ral45c00. Accessed December 15, 2006.
72. Enstrom JE, Kabat GC. Environmental tobacco smoke and tobacco related mortality in a prospective study of Californians, 1960-98. BMJ. 2003;326:1057-1067.
73. Thun M. Response to letter from Enstrom and Kabat. BMJ. 2003;327:E266-E267.
74. Enstrom JE, Kabat GC. Environmental tobacco smoke and coronary heart disease mortality in the United States: a meta-analysis and critique. Inhal Toxicol. 2006;18:199-210.
75. Inhalation Toxicology, Editorial Board. Informa Healthcare. Available at: www.tandf.co.uk/journals/journal.asp?issn=0895-8378&linktype= 5. Accessed February 2007.
76. Green C. Trip report: CIAR board meeting. April 27, 1994. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/rba13c00. Accessed December 15, 2006.
77. Environmental tobacco smoke R&D strategic plan issues, strategies and projects 1990 (900000). RJ Reynolds; 1990. Available at: www.tobaccodocuments. org/rjr/507850322-0378_D1.html. Accessed December 15, 2006.
78. Smith C, Sears S, Walker J, Deluca P. Environmental tobacco smoke: current assessment and future directions. November 2, 1992. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/xkw43d00. Accessed December 15, 2006.
79. Cole S, Swauger J, Smith C, Walker J. Calculation of permissible exposure limits for environmental tobacco smoke (ETS). September 1994. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/wky40d00. Accessed December 15, 2006.
80. Smith C, McKarns S. Smoker/nonsmoker comparative study: ETS-1. November 25, 1992. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/ ljf38c00. Accessed December 15, 2006.
81. Walker J, Nelson P, Smith C. ETS physiology II. March 4, 1996. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/zvd50d00. Accessed December 15, 2006.
82. Ling PM, Glantz SA. Tobacco industry consumer research on socially acceptable cigarettes. Tob Control. 2005;14:e3.
83. Cardiovascular effects of ETS exposure: comments on biological plausibility of proposed mechanisms. August 12, 1994. Tobacco Institute. http://legacy.library.ucsf.edu/tid/qhn50c00. Accessed December 15, 2006.
84. Smith C, Morgan W, Doolittle DJ, Fischer TH, Ruppert T, Scherer G. Urinary prostacyclin in nonsmokers living with smokers. Inhal Toxicol. 1998;10:431-441.
85. Smith C, Bombick D, McKarns S, Morton MJ, Morgan W, Doolittle DJ. Environmental Room Human Physiology Study using fresh diluted sidestream cigarette smoke. In: Proceedings of the 1996 CORESTA Congress. Yokahama, Japan; 1996:37-48.
86. Smith C, Sears SB. Respiratory effects of secondhand smoke. JAMA. 1999;281:1083. Letter.
87. Smith C, Steichen T, Fischer TH. Platelet aggregation in cigarette smokers: a meta-analysis. Inhal Toxicol. 1998;10:765-793.
88. Smith C, Scott S, Ryan B. Cardiovascular effects of odors. Toxicol Ind Health. 1999;15:595-601.
89. Smith CJ, Fischer TH, Sears SB. Environmental tobacco smoke, cardiovascular disease, and the nonlinear dose-response hypothesis. Toxicol Sci. 2000;54:462-472.
90. Smith CJ, Fischer TH, Heavner DL, Rumple MA, Bowman DL, Brown BG, Morton MJ, Doolittle DJ. Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2′-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke. Toxicol Sci. 2001;59:316-323.
91. Ong EK, Glantz SA. Constructing "sound science" and "good epidemiology": tobacco, lawyers, and public relations firms. Am J Public Health. 2001;91:1749-1757.
92. Smith C. January 18 conversation with Dr. Gary Huber. January 19, 1994. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/dhh97c00. Accessed December 15, 2006.
93. Rangemark C, Benthin G, Granstrom EF, Persson L, Winell S, Wennmalm A. Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age. Circulation. 1992;86:1495-1500.
94. Wennmalm A, Benthin G, Granstrom EF, Persson L, Petersson AS, Winell S. Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. Circulation. 1991;83:1698-1704.
95. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002;288:2008-2014.
96. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004;110:e489-e493.
97. Nasrallah R, Hebert RL. Prostacyclin signaling in the kidney: implications for health and disease. Am J Physiol Renal Physiol. 2005;289:F235-F246.
98. Hirschhorn N. Shameful science: four decades of the German tobacco industry's hidden research on smoking and health. Tob Control. 2000;9:242-248.
99. Gruning T, Gilmore AB, McKee M. Tobacco industry influence on science and scientists in Germany. Am J Public Health. 2006;96:20-32.
100. Bornhauser A, McCarthy J, Glantz SA. German tobacco industry's successful efforts to maintain scientific and political respectability to prevent regulation of secondhand smoke. Tob Control. 2006;15:e1.
101. Smith C. ETS urine thromboxane analysis. April 7, 1994. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/ttx83d00. Accessed December 15, 2006.
102. Coggins C. DABT. MS 0-97-373: behavior of urinary prostacyclin in nonsmokers living with smokers (C.J. Smith et al.). November 13, 1997. Lorillard. Available at: http://legacy.library.ucsf.edu/tid/erh23c00. Accessed December 15, 2006.
103. Pirkle JL, Bernert JT, Caudill SP, Sosnoff CS, Pechacek TF. Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke: 1988-2002. Environ Health Perspect. 2006;114:853-858.
104. Benowitz NL. Biomarkers of environmental tobacco smoke exposure. Environ Health Perspect. 1999;107(suppl 2):349-355.
105. Schmid P, Karanikas G, Kritz H, Pirich C, Stamatopoulos Y, Peskar BA, Sinzinger H. Passive smoking and platelet thromboxane. Thromb Res. 1996;81:451-460.
106. Smith C, McKarns S. ETS chamber study #2. February 8, 1995. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/vzy40d00. Accessed December 15, 2006.
107. Smith C, Bombick D, McKarns S, Morton M, Morgan W, Doolittle D. Environmental Room Human Physiology Study using fresh diluted sidestream cigarette smoke. December 15, 1998. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/gua65a00. Accessed December 15, 2006.
108. Eisner MD, Smith AK, Blanc PD. Bartenders' respiratory health after establishment of smoke-free bars and taverns. JAMA. 1998;280:1909-1914.
109. Eisner MD, Blanc PD. Response to "Respiratory Effects of Secondhand Smoke." JAMA. 1999;281:1083.
110. Hedqvist P, Gautam N, Lindbom L. Interactions between leukotrienes and other inflammatory mediators/modulators in the microvasculature. Am J Respir Crit Care Med. 2000;161:S117-S119.
111. Terres W, Beythien C, Kupper W, Bleifeld W. Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase: evidence for a possible role of inhibiting platelet activity in thrombolysis. Circulation. 1989;79:1309-1314.
112. Smith C, Bombick D, Ryan B, Morgan W, Doolittle DJ. Urinary mutagenicity in nonsmokers following exposure to fresh diluted sidestream cigarette smoke. Mutat Res. 2000;470:53-70.
113. Smith C. Transcript of the CORESTA conference. November 6, 1996. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/agf11d00. Accessed December 15, 2006.
114. Moskowitz S, Griscom T. CORESTA trip report. November 14, 1996. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/gxe46a00. Accessed December 15, 2006.
115. Hausberg M, Mark AL, Winniford MD, Brown RE, Somers VK. Sympathetic and vascular effects of short-term passive smoke exposure in healthy nonsmokers. Circulation. 1997;96:282-287.
116. Paustenbach D. Toxicological Sciences. Environmental tobacco smoke, cardiovascular disease and the nonlinear dose-response hypothesis. February 10, 1999. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/kvv20d00. Accessed December 15, 2006.
117. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 1995;92:1084-1088.
118. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
119. Scott S. Scherer study. October 24, 1997. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/qjf11d00. Accessed December 15, 2006.
120. Scherer G. R635. April 21, 1998. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/bir47d00. Accessed December 15, 2006.
121. Meeting of the Scientific Commission (WPA) of the German Cigarette Association (VDC). September 24, 1998. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/blf67e00. Accessed December 15, 2006.
122. Scherer G, Frank S, Riedel K, Meger-Kossien I, Renner T. Biomonitoring of exposure to polycyclic aromatic hydrocarbons of nonoccupationally exposed persons. Cancer Epidemiol Biomarkers Prev. 2000;9:373-380.
123. Smith C, Fischer TH. Subject: proposed measurements of the stable urinary metabolites of thromboxane (2,3-dinor-thromboxane b2) and prostacyclin (2,3-dinor-6-keto-prostaglandin F 1alpha) in three groups of subjects. October 14, 1998. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/ owk25a00. Accessed December 15, 2006.
124. Smith C. Response to reviewer's comments. September 26, 2000. RJ Reynolds. Available at: http://legacy.library.ucsf.edu/tid/qhv96a00. Accessed December 15, 2006.
125. Institute of Medicine. Stratton KR, Shetty P, Wallace R, Bondurant S, eds. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington DC: National Academy Press; 2001.
126. Robins R, ed. The Seduction of Harm Reduction: Proceedings from the September 2004 Summit. California Department of Health Services. 2005. Available at: http://www.dhs.ca.gov/tobacco/documents/pubs/ HarmReductProceedCompleteBooklet.pd. Accessed May 15, 2007.
127. WSA 20010000 proposed project plan development of in vivo model(s) for cardiovascular diseases. July 12, 2000. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/fwv15c00. Accessed December 15, 2006.
128. Sanders E. Re: Presentation on "cardiovascular" for Chantilly. May 3, 2000. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/ lxu85c00. Accessed December 15, 2006.
129. Sanders E. Re: ETS and CVD. September 7, 2000. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/drt39c00. Accessed December 15, 2006.
130. Sanders E. ETS and CVD. August 17. 2000. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/nuv39c00. Accessed December 15, 2006.
131. Sanders E. Fw: ETS study. August 31, 2001. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/ear94c00. Accessed December 15, 2006.
132. 2002 Worldwide scientific affairs planned projects. April 2002. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/tgg77c00. Accessed December 15, 2006.
133. Harm reduction evaluation guidelines. March 27, 2002. Philip Morris. Available at: http://legacy.library.ucsf.edu/tid/fil34a00. Accessed December 15, 2006.
134. Sanders E. Revised project sheets for the harm reduction guidelines. August 15, 2002. Philip Morris. Available at: http://legacy.library.ucsf.edu/ tid/yil34a00. Accessed December 15, 2006.
135. Bryan-Jones K, Bero LA. Tobacco industry efforts to defeat the occupational safety and health administration indoor air quality rule. Am J Public Health. 2003;93:585-592.
136. Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease. Circ Res. 2006;99:692-705.
137. Sargent RP, Shepard RM, Glantz SA. Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. BMJ. 2004;328:977-980.
138. Bartecchi C, Alsever RN, Nevin-Woods C, Thomas WM, Estacio RO, Bartelson BB, Krantz MJ. Reduction in the incidence of acute myocardial infarction associated with a citywide smoking ordinance. Circulation. 2006;114:1490-1496.
139. Barone-Adesi F, Vizzini L, Merletti F, Richiardi L. Short-term effects of Italian smoking regulation on rates of hospital admission for acute myocardial infarction. Eur Heart J. 2006;27:2468-2472.
140. Khuder S, Milz S, Jordan TR, Price JH, Silvestri K, Butler P. The impact of a smoking ban on hospital admissions for coronary heart disease. Prev Med. 2007;45:3-8.
141. Dinno A, Glantz S. Clean indoor air laws immediately reduce heart attacks. Prev Med. 2007;45:9-11.
142. Fichtenberg CM, Glantz SA. Association of the California Tobacco Control Program with declines in cigarette consumption and mortality from heart disease. N Engl J Med. 2000;343:1772-1777.
143. Fichtenberg CM, Glantz SA. Author reply correcting number deaths. N Engl J Med. 2001;344:1798-1799.
144. Shopland DR, Gerlach KK, Burns DM, Hartman AM, Gibson JT. State-specific trends in smoke-free workplace policy coverage: the current population survey tobacco use supplement, 1993 to 1999. J Occup Environ Med. 2001;43:680-686.
145. Ong MK, Glantz SA. Cardiovascular health and economic effects of smoke-free workplaces. Am J Med. 2004;117:32-38.
146. United States et al. v. Philip Morris USA et al, 449 F Supp. 2d 1, 2006 U.S. Dist. Lexis 57759 (D.D.C. 2006). Available at: dcd. ucscourts.gov/opinions/2006/99-2496-082006a.pdf (amended final opinion), dcd.uscourts.gov/opinions/2006/99-2496-082006b.pdf (final judgment and remedial order). Accessed May 15, 2007.
147. Schick S, Glantz S. Philip Morris toxicological experiments with fresh sidestream smoke: more toxic than mainstream smoke. Tob Control. 2005;14:396-404.
148. Schick S, Glantz SA. Sidestream cigarette smoke toxicity increases with aging and exposure duration. Tob Control. 2006;15:424-429.
149. Philip Morris USA. Smoking & health issues: secondhand smoke. Available at: http://pmusa.com/en/health_issues/secondhand_smoke.asp. Accessed March 15, 2007.
150. RJ Reynolds. Secondhand smoke: R.J. Reynolds Tobacco Company's Perspective. Available at: rjrt.com/smoking. Accessed September 30, 2006.
151. RJ Reynolds. Smoking and health: guiding principles and beliefs. Available at: http://www.rjrt.com/smoking/summaryCover.asp. Accessed March 15, 2007.